FY2025 EPS Forecast for Exact Sciences Increased by Analyst

Exact Sciences Corporation (NASDAQ:EXAS) – Investment analysts at Leerink Partnrs upped their FY2025 earnings estimates for shares of Exact Sciences in a research note issued on Thursday, August 7th. Leerink Partnrs analyst P. Souda now anticipates that the medical research company will post earnings of $0.41 per share for the year, up from their prior estimate of $0.28. The consensus estimate for Exact Sciences’ current full-year earnings is ($0.58) per share. Leerink Partnrs also issued estimates for Exact Sciences’ Q4 2026 earnings at $0.39 EPS, FY2026 earnings at $1.20 EPS and FY2027 earnings at $2.04 EPS.

EXAS has been the topic of a number of other research reports. Royal Bank Of Canada reiterated a “sector perform” rating and issued a $46.00 target price (down previously from $54.00) on shares of Exact Sciences in a research report on Thursday. UBS Group decreased their target price on shares of Exact Sciences from $61.00 to $53.00 and set a “neutral” rating on the stock in a research report on Thursday. Cowen reiterated a “buy” rating on shares of Exact Sciences in a research report on Thursday. Robert W. Baird lifted their target price on shares of Exact Sciences from $69.00 to $72.00 and gave the stock an “outperform” rating in a research report on Friday, May 2nd. Finally, Wall Street Zen upgraded shares of Exact Sciences from a “hold” rating to a “buy” rating in a research report on Saturday. Three research analysts have rated the stock with a hold rating, twenty-one have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $68.62.

Exact Sciences Price Performance

Shares of NASDAQ:EXAS opened at $40.99 on Monday. The stock has a market cap of $7.76 billion, a PE ratio of -7.55, a PEG ratio of 4.74 and a beta of 0.93. The company’s fifty day moving average is $51.55 and its 200 day moving average is $50.00. Exact Sciences has a 52 week low of $38.81 and a 52 week high of $72.83. The company has a quick ratio of 2.56, a current ratio of 2.89 and a debt-to-equity ratio of 0.94.

Exact Sciences (NASDAQ:EXAS) last posted its quarterly earnings data on Wednesday, August 6th. The medical research company reported $0.22 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.24. Exact Sciences had a negative net margin of 34.19% and a negative return on equity of 1.75%. The company had revenue of $811.09 million during the quarter, compared to the consensus estimate of $774.43 million. During the same period in the previous year, the firm posted ($0.09) EPS. The firm’s revenue was up 16.0% compared to the same quarter last year.

Institutional Investors Weigh In On Exact Sciences

A number of large investors have recently modified their holdings of the stock. Great Lakes Advisors LLC boosted its stake in shares of Exact Sciences by 3.7% during the 1st quarter. Great Lakes Advisors LLC now owns 4,971 shares of the medical research company’s stock valued at $215,000 after purchasing an additional 178 shares in the last quarter. Nissay Asset Management Corp Japan ADV boosted its stake in Exact Sciences by 0.8% during the first quarter. Nissay Asset Management Corp Japan ADV now owns 22,432 shares of the medical research company’s stock worth $971,000 after acquiring an additional 187 shares in the last quarter. DekaBank Deutsche Girozentrale boosted its stake in Exact Sciences by 0.4% during the second quarter. DekaBank Deutsche Girozentrale now owns 58,333 shares of the medical research company’s stock worth $3,127,000 after acquiring an additional 217 shares in the last quarter. OneDigital Investment Advisors LLC boosted its stake in Exact Sciences by 0.3% during the first quarter. OneDigital Investment Advisors LLC now owns 100,872 shares of the medical research company’s stock worth $4,367,000 after acquiring an additional 270 shares in the last quarter. Finally, IFP Advisors Inc boosted its stake in Exact Sciences by 6.5% during the second quarter. IFP Advisors Inc now owns 4,466 shares of the medical research company’s stock worth $237,000 after acquiring an additional 273 shares in the last quarter. Institutional investors own 88.82% of the company’s stock.

Insider Buying and Selling at Exact Sciences

In other news, Director Katherine S. Zanotti sold 3,207 shares of Exact Sciences stock in a transaction dated Friday, June 13th. The shares were sold at an average price of $53.20, for a total transaction of $170,612.40. Following the sale, the director owned 72,759 shares of the company’s stock, valued at approximately $3,870,778.80. The trade was a 4.22% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 1.20% of the company’s stock.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.